NOVAVAX 8-K Summary (Nov 3, 2025)

NOVAVAX announced a significant regulatory event affecting its product Nuvaxovid™.

• The FDA approved the transfer of the marketing authorization for Nuvaxovid™ to Sanofi Pasteur Inc.
• Triggered Milestone: This transfer initiates a $25 million milestone payment from Sanofi under the existing agreement.
• Timing: Novavax anticipates receipt of this cash payment in the First Quarter of 2026.

This information was furnished via an Item 8.01 filing, supported by an Exhibit 99.1 press release. The report includes standard cautionary n